Spooner K, et al. - In patients with persistent macular edema secondary to retinal vein occlusions (RVO), researchers systematically reviewed anatomical and functional outcomes after switching therapy from bevacizumab and/or ranibizumab to aflibercept. They searched EMBASE, PubMed and Cochrane databases up to June 2017 for studies assessing aflibercept for the treatment of persistent macular edema secondary to branch and central RVO. Mean central macular thickness (CMT) was found to improve significantly after switch to aflibercept at 6, but not 12 months. Persistent macular edema secondary to RVO may be improved by switching from bevacizumab/ranibizumab to aflibercept. Nonetheless, possible limitation was noted in the potential of visual recovery.